Abstract 702P
Background
Human leukocyte antigens (HLAs) are expressed in a variety of cells, including cancer cells and immune cells. Recent studies have shown that germline HLA gene zygosity, supertype and individual HLA genotypes may be associated with immunotherapy (IO) outcomes. We aimed to evaluate whether germline HLA-A gene haplotype and zygosity is associated with response to IO.
Methods
Pts enrolled in phase 1 clinical trials in the Vall d´Hebron Institute of Oncology Early Drug Development Unit with available HLA-A testing were reviewed. Median progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.
Results
From 2021 to 2023 a total of 247 eligible pts were reviewed. Median age was 59y, 63% female, main types of tumor with positive HLA biomarker were colorectal/anal cancer 19% (47pts), gynecological tumors 14%(34pts); and breast cancer 14% (34pts). Alleles present at >5% samples: 02:01:01 25%, 01:01:01 11%, 03:01:01 11%, 24:02:01 9%, 29:02:01 8%. Twenty-five (10.20%) pts presented HLA-A homozygosis. Homozygosis occurred in the most common haplotypes: 02:01:01 (14pts), 01:01:01 (2pts), 03:01:01 (4pts%), 24:02:01 (2pts%) and 29:02:01 (2pts). Eighty-five (34.5%) pts received IO; main types of tumors that received IO were genitourinary tumors 67% (10pts), gynecological tumors 45% (16pts) and colorectal/anal tumors 27% (13pts). Pts treated with anti-PD1 were 17 (20%), anti-PDL1 17 (20%) and other combinations 20 (24%). Twelve patients (17%) had PR, and thirty eight (45%) SD. Overal PFS and OS was 6.1 months and 29.6 months respectively. Presence of 03:01:01 was associated with a higher likelihood of response. Six pts with HLA homozygosis received inmunotherapy, all of them achieved SD as best response (NS).
Conclusions
Prevalence of HLA 02:01:01 in our population is significantly lower than reported in other populations. Presence of Homozygoses was not significantly associated with lack of response to inmunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research has been funded by CaixaResearch Advanced Oncology Research Program supported by Fundació La Caixa, by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17